siRNA delivery strategies: A comprehensive review of recent developments

Nanomaterials

Volumn 7, Issue 4, 2017, Pages

  Tatiparti, Katyayani ^a   Sau, Samaresh ^a   Kashaw, Sushil Kumar ^a,b   Iyer, Arun K ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b DR H S GOUR UNIVERSITY   (India)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer therapy; Delivery systems; Gene delivery; Nanoparticles; RNAi; siRNA; Targeted delivery; Tumor

Indexed keywords

EID: 85018490272     PISSN: None     EISSN: 20794991     Source Type: Journal    
DOI: 10.3390/nano7040077     Document Type: Review

References (83)

1. Young, S.W.S.; Stenzel, M.; Yang, J.L. Nanoparticle-siRNA: A potential cancer therapy? Crit. Rev. Oncol. Hematol. 2016, 98, 159–169. [CrossRef] [PubMed]
2. Dogini, D.B.; Pascoal, V.D.A.B.; Avansini, S.H.; Vieira, A.S.; Pereira, T.C.; Lopes-Cendes, I. The new world of RNAs. Genet. Mol. Biol. 2014, 37, 285–293. [CrossRef] [PubMed]
3. Castanotto, D.; Rossi, J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457, 426–433. [CrossRef] [PubMed]
4. Sashital, D.G.; Doudna, J.A. Structural insights into RNA interference. Curr. Opin. Struct. Biol. 2010, 20, 90–97. [CrossRef] [PubMed]
5. Martinez, J.; Patkaniowska, A.; Urlaub, H.; Lührmann, R.; Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110, 563–574. [CrossRef]
6. Meister, G.; Tuschi, T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431, 343–349. [CrossRef] [PubMed]
7. Li, J.; Xue, S.; Mao, Z.W. Nanoparticle delivery systems for siRNA-based therapeutics. J. Mater. Chem. B 2016, 4, 6620–6639. [CrossRef]
8. Dykxhoorn, D.M.; Novina, C.D.; Sharp, P.A. Killing the messenger: Short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 2003, 4, 457–467. [CrossRef] [PubMed]
9. Van de Veire, S.; Stalmans, I.; Heindryckx, F.; Oura, H.; Tijeras-Raballand, A.; Schmidt, T.; Loges, S.; Albrecht, I.; Jonckx, B.; Vinckier, S.; et al. Pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010, 141, 178–190. [CrossRef] [PubMed]
10. Zhao, M.; Sun, J.; Zhao, Z. Synergetic regulatory networks mediated by oncogene-driven microRNAs and transcription factors in serous ovarian cancer. Mol. Biosyst. 2013, 9, 3187–3198. [CrossRef] [PubMed]
11. Wu, S.Y.; Lopez-Berestein, G.; Calin, G.A.; Sood, A.K. RNAi Therapies: Drugging the Undruggable. Sci. Transl. Med. 2014, 6, 240–247. [CrossRef] [PubMed]
12. Davidson, B.L.; McCray, P.B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12, 329–340. [CrossRef] [PubMed]
13. Fellmann, C.; Lowe, S.W. Stable RNA interference rules for silencing. Nat. Cell Biol. 2014, 16, 10–18. [CrossRef] [PubMed]
14. Lee, S.J.; Kim, M.J.; Kwon, I.C.; Roberts, T.M. Delivery strategies and potential targets for siRNA in major cancer types. Adv. Drug Deliv. Rev. 2015, 104, 2–15.
15. Wang, J.; Mi, P.; Lin, G.; Wáng, Y.X.J.; Liu, G.; Chen, X. Imaging-guided delivery of RNAi for anticancer treatment. Adv. Drug Deliv. Rev. 2015, 104, 44–60.
16. Pai, S.; Lin, Y.Y.; Macaes, B.; Meneshian, A.; Hung, C.F.; Wu, T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 2006, 13, 464–477. [CrossRef] [PubMed]
17. Resnier, P.; Montier, T.; Mathieu, V.; Benoit, J.P.; Passirani, C. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013, 34, 6429–6443. [CrossRef] [PubMed]
18. Jin, H.; Kim, A.; Miyata, K.; Kataoka, K.; Kim, H.J.; Kim, A.; Miyata, K.; Kataoka, K. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv. Drug Deliv. Rev. 2016, 104, 61–77.
19. Haussecker, D. Current issues of RNAi therapeutics delivery and development. J. Control. Release 2014, 195, 49–54. [CrossRef] [PubMed]
20. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63, 136–151. [CrossRef] [PubMed]
21. Kobayashi, H.; Watanabe, R.; Choyke, P.L. Improving conventional enhanced permeability and retention (EPR) effects; What is the appropriate target? Theranostics 2014, 4, 81–89. [CrossRef] [PubMed]
22. Jarad, G.; Miner, J.H. Update on the glomerular filtration barrier. Curr. Opin. Nephrol. Hypertens. 2009, 18, 226–232. [CrossRef] [PubMed]
23. Wartiovaara, J.; Öfverstedt, L.G.; Khoshnoodi, J.; Zhang, J.; Mäkelä, E.; Sandin, S.; Ruotsalainen, V.; Cheng, R.H.; Jalanko, H.; Skoglund, U.; et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J. Clin. Investig. 2004, 114, 1475–1483. [CrossRef] [PubMed]
24. Huang, Y.; Hong, J.; Zheng, S.; Ding, Y.; Guo, S.; Zhang, H.; Zhang, X.; Du, Q.; Liang, Z. Elimination pathways of systemically delivered siRNA. Mol. Ther. 2011, 19, 381–385. [CrossRef] [PubMed]
25. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 2001, 53, 283–318.
26. [PubMed]
27. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14, 1310–1316. [CrossRef] [PubMed]
28. Huang, K.; Ma, H.; Liu, J.; Huo, S.; Kumar, A.; Wei, T.; Zhang, X.; Jin, S.; Gan, Y.; Wang, P.C.; et al. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 2012, 6, 4483–4493. [CrossRef] [PubMed]
29. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 1989, 49, 6449–6465.
30. [PubMed]
31. Li, L.; Wang, R.; Wilcox, D.; Zhao, X.; Song, J.; Lin, X.; Kohlbrenner, W.M.; Fesik, S.W.; Shen, Y. Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther. 2012, 19, 775–780. [CrossRef] [PubMed]
32. Meade, B.R.; Dowdy, S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 2007, 59, 134–140. [CrossRef] [PubMed]
33. Rozema, D.B.; Lewis, D.L.; Wakefield, D.H.; Wong, S.C.; Klein, J.J.; Roesch, P.L.; Bertin, S.L.; Reppen, T.W.; Chu, Q.; Blokhin, A.V.; et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. USA 2007, 104, 12982–12987. [CrossRef] [PubMed]
34. Konishi, M.; Kawamoto, K.; Izumikawa, M.; Kuriyama, H.; Yamashita, T. Gene transfer into guinea pig cochlea using adeno-associated virus vectors. J. Gene Med. 2008, 10, 610–618. [CrossRef] [PubMed]
35. Chu, T.C.; Twu, K.Y.; Ellington, A.D.; Levy, M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006, 34, e73. [CrossRef] [PubMed]
36. Mindell, J.A. Lysosomal acidification mechanisms. Annu. Rev. Physiol. 2012, 74, 69–86. [CrossRef] [PubMed]
37. Appelqvist, H.; Wäster, P.; Kågedal, K.; Öllinger, K. The lysosome: Fromwaste bag to potential therapeutic target. J.Mol. Cell Biol. 2013, 5, 214–226. [CrossRef] [PubMed]
38. Sonawane, N.D.; Szoka, F.C.; Verkman, A.S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 2003, 278, 44826–44831. [CrossRef] [PubMed]
39. Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.Y.; Stebbing, D.; Crosley, E.J.; Yaworski, E.; et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28, 172–176. [CrossRef] [PubMed]
40. Jackson, A.L.; Burchard, J.; Schelter, J.; Chau, B.N.; Cleary, M.; Lim, L.; Linsley, P.S. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006, 12, 1179–1187. [CrossRef] [PubMed]
41. Qiu, S.; Adema, C.M.; Lane, T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 2005, 33, 1834–1847. [CrossRef] [PubMed]
42. Hornung, V.; Guenthner-Biller, M.; Bourquin, C.; Ablasser, A.; Schlee, M.; Uematsu, S.; Noronha, A.; Manoharan, M.; Akira, S.; de Fougerolles, A.; et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11, 263–270. [CrossRef] [PubMed]
43. Judge, A.D.; Sood, V.; Shaw, J.R.; Fang, D.; McClintock, K.; MacLachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 2005, 23, 457–462. [CrossRef] [PubMed]
44. Li, W.; Hu, Z.F.; Chen, B.; Ni, G.X. Response of C2C12 myoblasts to hypoxia: The relative roles of glucose and oxygen in adaptive cellular metabolism. BioMed Res. Int. 2013, 2013, 326346. [CrossRef] [PubMed]
45. Kim, T.; Hyeon, T. Applications of inorganic nanoparticles as therapeutic agents. Nanotechnology 2014, 25, 12001. [CrossRef] [PubMed]
46. Mody, V.V.; Cox, A.; Shah, S.; Singh, A.; Bevins, W.; Parihar, H. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl. Nanosci. 2013, 4, 385–392. [CrossRef]
47. Alhaddad, A.; Adam, M.P.; Botsoa, J.; Dantelle, G.; Perruchas, S.; Gacoin, T.; Mansuy, C.; Lavielle, S.; Malvy, C.; Treussart, F.; et al. Nanodiamond as a vector for siRNA delivery to Ewing sarcoma cells. Small 2011, 7, 3087–3095. [CrossRef] [PubMed]
48. Zhang, L.; Li, Y.; Yu, J.C. Chemical modification of inorganic nanostructures for targeted and controlled drug delivery in cancer treatment. J. Mater. Chem. B 2014, 2, 452–470. [CrossRef]
49. Ryu, J.H.; Lee, S.; Son, S.; Kim, S.H.; Leary, J.F.; Choi, K.; Kwon, I.C. Theranostic nanoparticles for future personalized medicine. J. Control. Release 2014, 190, 477–484. [CrossRef] [PubMed]
50. Muthu, M.S.; Leong, D.T.; Mei, L.; Feng, S.S. Nanotheranostics-application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4, 660–677. [CrossRef] [PubMed]
51. Endres, T.K.; Beck-Broichsitter, M.; Samsonova, O.; Renette, T.; Kissel, T.H. Self-assembled biodegradable amphiphilic PEG-PCL-lPEI triblock copolymers at the borderline between micelles and nanoparticles designed for drug and gene delivery. Biomaterials 2011, 32, 7721–7731. [CrossRef] [PubMed]
52. Sun, T.M.; Du, J.Z.; Yao, Y.D.; Mao, C.Q.; Dou, S.; Huang, S.Y.; Zhang, P.Z.; Leong, K.W.; Song, E.W.; Wang, J. Simultaneous delivery of siRNA and paclitaxel via a “two-in-one” micelleplex promotes synergistic tumor suppression. ACS Nano 2011, 5, 1483–1494. [CrossRef] [PubMed]
53. Yu, H.; Zou, Y.; Wang, Y.; Huang, X.; Huang, G.; Sumer, B.D.; Boothman, D.A.; Gao, J. Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery. ACS Nano 2011, 5, 9246–9255. [CrossRef] [PubMed]
54. Gandhi, N.S.; Tekade, R.K.; Chougule, M.B. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances. J. Control. Release 2014, 194, 238–256. [CrossRef] [PubMed]
55. Smeyne, M.; Smeyne, R.J. Glutathione metabolism and Parkinson’s disease. Free Radic. Biol. Med. 2013, 62, 13–25. [CrossRef] [PubMed]
56. Ryu, J.-H.; Chacko, R.T.; Jiwpanich, S.; Bickerton, S.; Babu, R.P.; Thayumanavan, S. Self-cross-linked polymer nanogels: A versatile nanoscopic drug delivery platform supporting info. J. Am. Chem. Soc. 2010, 3, 17227–17235. [CrossRef] [PubMed]
57. Circu, M.L.; Aw, T.Y. Glutathione and modulation of cell apoptosis. Biochim. Biophys. Acta 2012, 1823, 1767–1777. [CrossRef] [PubMed]
58. Neri, D.; Supuran, C.T. Interfering with pH regulation in tumours as a therapeutic strategy. Nat. Rev. Drug Discov. 2011, 10, 767–777. [CrossRef] [PubMed]
59. Li, J.; Yu, X.; Wang, Y.; Yuan, Y.; Xiao, H.; Cheng, D.; Shuai, X. A reduction and pH dual-sensitive polymeric vector for long-circulating and tumor-targeted siRNA delivery. Adv. Mater. 2014, 26, 8217–8224. [CrossRef] [PubMed]
60. Hama, S.; Itakura, S.; Nakai, M.; Nakayama, K.; Morimoto, S.; Suzuki, S.; Kogure, K. Overcoming the polyethylene glycol dilemma via pathological environment-sensitive change of the surface property of nanoparticles for cellular entry. J. Control. Release 2015, 206, 67–74. [CrossRef] [PubMed]
61. Wang, H.X.; Yang, X.Z.; Sun, C.Y.; Mao, C.Q.; Zhu, Y.H.; Wang, J. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014, 35, 7622–7634. [CrossRef] [PubMed]
62. Li, H.; Yu, S.S.; Miteva, M.; Nelson, C.E.; Werfel, T.; Giorgio, T.D.; Duvall, C.L. Matrix metalloproteinase responsive, proximity-activated polymeric nanoparticles for siRNA delivery. Adv. Funct. Mater. 2013, 23, 3040–3052. [CrossRef] [PubMed]
63. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the yumor microenvironment. Cell 2010, 141, 52–67. [CrossRef] [PubMed]
64. Decock, J.; Thirkettle, S.; Wagstaff, L.; Edwards, D.R. Matrix metalloproteinases: Protective roles in cancer. J. Cell. Mol. Med. 2011, 15, 1254–1265. [CrossRef] [PubMed]
65. Bode, W.; Maskos, K. Matrix metalloproteinases. Encycl. Inorg. Bioinorg. Chem. 2011, 181, 1895–1899.
66. Nair, J.K.; Willoughby, J.L.S.; Chan, A.; Charisse, K.; Alam, M.R.; Wang, Q.; Hoekstra, M.; Kandasamy, P.; Kelin, A.V.; Milstein, S.; et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 2014, 136, 16958–16961. [CrossRef] [PubMed]
67. Cruz, L.J.; Tacken, P.J.; Fokkink, R.; Figdor, C.G. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials 2011, 32, 6791–6803. [CrossRef] [PubMed]
68. Xu, Y.; Szoka, F.C.J. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35, 5616–5623. [CrossRef] [PubMed]
69. Hafez, I.M.; Maurer, N.; Cullis, P.R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001, 8, 1188–1196. [CrossRef] [PubMed]
70. Hatakeyama, H.; Akita, H.; Harashima, H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev. 2011, 63, 152–160. [CrossRef] [PubMed]
71. Ashley, C.E.; Carnes, E.C.; Epler, K.E.; Padilla, D.P.; Phillips, G.K.; Castillo, R.E.; Wilkinson, D.C.; Wilkinson, B.S.; Burgard, C.A.; Kalinich, R.M.; et al. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano 2012, 6, 2174–2188. [CrossRef] [PubMed]
72. Elbakry, A.; Zaky, A.; Liebl, R.; Rachel, R.; Goepferich, A.; Breunig, M. Layer-by-layer assembled gold nanoparticles for sirna delivery. Nano Lett. 2009, 9, 2059–2064. [CrossRef] [PubMed]
73. Yamaguchi, M. Regulatory role of regucalcin in heart calcium signaling: Insight into cardiac failure. Biomed. Rep. 2014, 2, 303–308. [CrossRef] [PubMed]
74. Suma, T.; Miyata, K.; Anraku, Y.; Watanabe, S.; Christie, R.J.; Takemoto, H.; Shioyama, M.; Gouda, N.; Ishii, T.; Nishiyama, N.; et al. Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG. ACS Nano 2012, 6, 6693–6705. [CrossRef] [PubMed]
75. Li, J.; Chen, Y.C.; Tseng, Y.C.; Mozumdar, S.; Huang, L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 2010, 142, 416–421. [CrossRef] [PubMed]
76. Kakizawa, Y.; Furukawa, S.; Ishii, A.; Kataoka, K. Organic-inorganic hybrid-nanocarrier of siRNA constructing through the self-assembly of calcium phosphate and PEG-based block aniomer. J. Control. Release 2006, 111, 368–370. [CrossRef] [PubMed]
77. Pittella, F.; Zhang, M.; Lee, Y.; Kim, H.J.; Tockary, T.; Osada, K.; Ishii, T.; Miyata, K.; Nishiyama, N.; Kataoka, K. Enhanced endosomal escape of siRNA-incorporating hybrid nanoparticles from calcium phosphate and PEG-block charge-conversional polymer for efficient gene knockdown with negligible cytotoxicity. Biomaterials 2011, 32, 3106–3114. [CrossRef] [PubMed]
78. Kim, H.J.; Takemoto, H.; Yi, Y.; Zheng, M.; Maeda, Y.; Chaya, H.; Hayashi, K.; Mi, P.; Pittella, F.; Christie, R.J.; et al. Precise engineering of siRNA delivery vehicles to tumors using polyion complexes and gold nanoparticles. ACS Nano 2014, 8, 8979–8991. [CrossRef] [PubMed]
79. Jensen, S.A.; Day, E.S.E.; Ko, C.H.C.; Hurley, L.A.; Luciano, J.P.; Kouri, F.M.; Merkel, T.J.; Luthi, A.J.; Patel, P.C.; Cutler, J.I.; et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl. Med. 2013, 5, 209ra152. [CrossRef] [PubMed]
80. Hom, C.; Lu, J.; Liong, M.; Luo, H.; Li, Z.; Zink, J.I.; Tamanoi, F. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 2011, 6, 1185–1190. [CrossRef] [PubMed]
81. Li, J.; Yang, Y.; Huang, L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J. Control. Release 2012, 158, 108–114. [CrossRef] [PubMed]
82. Guo, J.; Rahme, K.; Fitzgerald, K.A.; Holmes, J.D.; O’Driscoll, C.M. Biomimetic gold nanocomplexes for gene knockdown: Will gold deliver dividends for small interfering RNA nanomedicines? Nano Res. 2015, 8, 3111–3140. [CrossRef]
83. Deng, Z.J.; Morton, S.W.; Ben-Akiva, E.; Dreaden, E.C.; Shopsowitz, K.E.; Hammond, P.T. Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment. ACS Nano 2013, 7, 9571–9584. [CrossRef] [PubMed]